Quantitative and qualitative composition of lymphocyte populations and subpopulations in patients with varying severity of a new coronavirus infection
- Authors: Ivanova I.A.1, Trufanova A.A.1, Filippenko A.V.1, Omelchenko N.D.1, Noskov A.K.1, Chemisova O.S.1
-
Affiliations:
- Rostov-on-Don Anti-Plague Institute of Rospotrebnadzor
- Issue: Vol 12, No 3 (2022)
- Pages: 505-510
- Section: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/2220-7619/article/view/119072
- DOI: https://doi.org/10.15789/2220-7619-QAQ-1818
- ID: 119072
Cite item
Full Text
Abstract
SARS-CoV-2 can cause a decrease in the number of lymphocytes and their functional activity. In patients with COVID-19, especially with a severe course of the disease, a decrease in the quantitative composition of the main populations of lymphocytes is recorded. These indicators do not recover for a long time after recovery. However, it is still not known how long the quantitative and qualitative changes in the composition of lymphocytes will last and whether the severity of the infection affects this process. The aim of our study was to assess the quantitative and qualitative composition of the main populations and subpopulations of lymphocytes in patients with a new coronavirus infection of varying severity. 65 patients with a new coronavirus infection were examined. The average age of the subjects was 47.3±14.5 years. The volunteers were divided into three groups according to the severity of the infection: asymptomatic (n = 21); moderate (n = 32); severe (n = 12). The relative and absolute number of T-lymphocytes (CD3+), T-helper cells (CD3+CD4+), cytotoxic lymphocytes (CD3+CD8+), natural killers (CD3–CD16+CD56+), TNK-lymphocytes (CD3+CD16–CD56+) and B-lymphocytes (CD45+CD19+) were determined. To calculate the percentage of lymphocytes, whole blood was lysed with OPTILYSE C solution (Beckman Coulter, USA) and stained with monoclonal antibodies CD3+-FITC/CD8+-ECD/CD4+-PC5/CD16+CD56+PE and CD45+-Pacific Blue/CD19+-PC5 (Beckman Coulter, USA). Cytofluorometry was performed on a flow cytofluorometer “Navios™” (Beckman Coulter, USA). The results of our studies showed that there were no statistically significant changes in the relative and absolute number of immunocompetent cells in asymptomatic patients with a new coronavirus infection, compared with the control group. With an average severity of the disease, a decrease in the relative and absolute content of CD3+ and CD8+ lymphocytes was revealed, these indicators were restored to control values six months after recovery. In patients with severe infection, there was a decrease in the relative and absolute number of T cells and cytotoxic lymphocytes. These values remained significantly below normal for six months and returned to normal only seven to eight months after recovery. Also, the volunteers of this group were found to have a decrease in the number of natural killers and TNK cells. Thus, the data obtained by us indicate that pathological changes concerning the relative and absolute number of the main populations and subpopulations of lymphocytes in patients with COVID-19 depend on the severity of the disease. The number of T-lymphocytes, cytotoxic lymphocytes, natural killer cells, that is, populations of cells that play a crucial role in effective antiviral protection, has been reduced in those who have undergone a new coronavirus infection in moderate and severe form. This information can be useful for expanding methodological approaches to the diagnosis, treatment of a new coronavirus infection, as well as measures for the rehabilitation of those who have suffered it.
Full Text
##article.viewOnOriginalSite##About the authors
Inna A. Ivanova
Rostov-on-Don Anti-Plague Institute of Rospotrebnadzor
Author for correspondence.
Email: inna_ivanova_1968@inbox.ru
ORCID iD: 0000-0001-7068-4071
PhD (Biology), Leading Researcher with Acting Head of the Immunology Laboratory
Russian Federation, Rostov-on-DonA. A. Trufanova
Rostov-on-Don Anti-Plague Institute of Rospotrebnadzor
Email: Nastyasia61@mail.ru
ORCID iD: 0000-0002-4770-5994
Junior Researcher, Laboratory of Immunology
Russian Federation, Rostov-on-DonA. V. Filippenko
Rostov-on-Don Anti-Plague Institute of Rospotrebnadzor
Email: filippenko.annushka@mail.ru
ORCID iD: 0000-0002-1103-4244
Junior Researcher, Laboratory of Immunology
Russian Federation, Rostov-on-DonN. D. Omelchenko
Rostov-on-Don Anti-Plague Institute of Rospotrebnadzor
Email: plague@aaanet.ru
ORCID iD: 0000-0001-5208-7724
PhD (Medicine), Senior Researcher Laboratory of Immunology
Russian Federation, Rostov-on-DonA. K. Noskov
Rostov-on-Don Anti-Plague Institute of Rospotrebnadzor
Email: plague@aaanet.ru
ORCID iD: 0000-0003-0550-2221
Director
Russian Federation, Rostov-on-DonO. S. Chemisova
Rostov-on-Don Anti-Plague Institute of Rospotrebnadzor
Email: plague@aaanet.ru
ORCID iD: 0000-0002-4059-2878
Acting Head of the Laboratory “Сollection of Pathogenic Microorganisms”
Russian Federation, Rostov-on-DonReferences
- Chen Z., Wherry E.J. T cell responses in patients with COVID-19. Nat. Rev. Immunol., 2020, vol. 20, pp. 529–536. doi: 10.1038/s41577-020-0402-6
- Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L., Chen L., Li M., Liu Y., Wang G. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19). Front. Immunol., 2020, vol. 1, no. 11: 827. doi: 10.3389/fimmu.2020.00827
- Fan В.Е., Chong V.C., Chan S.S. W., Lim G., Lim K.G.E., Tan G.B., Mucheli S.S., Kuperan P., Ong K. Hematologic parameters in patients with COVID-19 infection. Am. J. Hematol., 2020, vol. 95, no. 6, pp. E131–E134. doi: 10.1002/ajh.25774
- Ganji A., Farahani I., Khansarinejad B., Ghazavi A., Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol. Dis., 2020, vol. 83: 102437. doi: 10.1016/j.bcmd.2020.102437
- Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S., Du B., Li L.-J., Zeng G., Yuen K. Y., Chen R.-C., Tang C.-L., Wang T., Chen P.-Y., Xiang J., Li S.-Y., Wang J.-L., Liang Z.-J., Peng, Y.-X., Wei L., Liu Y., Hu Y.-H., Peng P., Wang J.-M., Liu J.-Y., Chen Z., Li G., Zheng Z.-J., Qiu S.-Q., Luo J., Ye C.-J., Zhu S.-Y., Zhong N.-S. Clinical characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med., 2020, vol. 382, no.18, pp. 1708–1720. doi: 10.1056/NEJMoa2002032
- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., W. Wu, Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, no. 10223, pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5
- Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg. Microb. Infect., 2020, vol. 9, no. 1, pp. 727–732. doi: 10.1080/22221751.2020.1746199
- Lippi G., Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin. Chem. Lab. Med., 2020, vol. 25, no. 58 (7), pp. 1131–1134. doi: 10.1515/cclm-2020-0198
- Liu J., Li S., Liu J., Liang B., Wang X., Wang H., Li W., Tong Q., Yi J., L. Zhao, Xiong L., Guo C., Tian J., Luo J., Yao J.,. Pang R., Shen H., Peng C., Liu T., Zhang Q., Wu J., Xu L., Lu S., Wang B., Weng Z., Han C., Zhu H., Zhou R., Zhou H., Chen X., Ye P., Zhu B., Wang L., Zhou W., He S., He Y., Jie S., Wei P., Zhang J., Lu Y., Wang W., Zhang L., Li L., Zhou F., Wang J., Dittmer U., Lu M., Hu Y., Yang D., Zheng X. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. eBioMedicine, 2020, vol. 55: 102763. doi: 10.1016/j.ebiom.2020.102763
- Manickam C., Sugawara S., Reeves R.K. Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. PLoS Pathog., 2020, vol. 16, no. 8: e1008820. doi: 10.1371/journal.ppat.1008820
- Peng J., Qi D., Yuan G., Deng X., Mei Y., Feng L., Wang D. Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): a multicenter, cross-sectional study. J. Clin. Lab. Anal., 2020, vol. 34, no. 10: e23475. doi: 10.1002/jcla.23475
- Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., Tian D.-S., Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., Tian D.-S. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis., 2020, vol. 71, no. 15, pp. 762–768. doi: 10.1093/cid/ciaa248.
- Rokni M., Ghasemi V., Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS. Rev. Med. Virol., 2020, vol. 30, no. 3: e2107. doi: 10.1002/rmv.2107
- Vaninov N. In the eye of the COVID-19 cytokine storm. Nat. Rev. Immunol., 2020, vol. 20, no. 5: 277. doi: 10.1038/s41577-020-0305-6
- Wan S., Yi Q., Fan S., Lv J., Zhang X., Guo L., Lang C., Xiao Q., Xiao K., Yi Z., Qiang M., Xiang J., Zhang B., Chen Y., Gao C. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br. J. Haematol., 2020, vol. 189, no. 3, pp. 428–437. doi: 10.1111/bjh.16659
- Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, vol. 323, no. 11: 1061. doi: 10.1001/jama.2020.1585
- Yang J., Zhong M., Zhang E., Hong K., Yang Q., Zhou D., Xia J., Chen Y.-Q., Sun M., Zhao B., Xiang J., Liu Y., Han Y., Zhou X., Huang C., Shang Y., Yan H. Broad phenotypic alterations and potential dysfunctions of lymphocytes in COVID-19 recovered individuals. J. Mol. Cell Biol., 2021, vol. 13, no. 3, pp. 197–209. doi: 10.1093/jmcb/mjab014
- Zheng H.-Y., Zhang M., Yang C.-X., Zhang N., Wang X.-C., Yang X.-P., Dong X.-Q., Zheng Y.-T. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell. Mol. Immunol., 2020, vol. 17, no. 5, pp. 541–543. doi: 10.1038/s41423-020-0401-3
Supplementary files
